Sentence examples for cage infection from inspiring English sources

The methicillin-susceptible S. aureus (MSSA) strain I20 is a previously described clinical isolate from catheter-related sepsis, which is highly virulent in the rat model of chronic S. aureus tissue cage infection [ 33, 43].

A first study (sponsored by Lilly and referred to as the daptomycin no 1-study) was initiated in 1991 for evaluating daptomycin in the rat model of tissue cage infections.

Nevertheless, application to the rat model of tissue cage infections of AUC/MIC ratio breakpoints recorded in neutropenic mice models is probably not justified because of important differences between these animal models.

The more rapid in vitro elimination rate of MSSA strain I20 by daptomycin compared to oxacillin and vancomycin may be one factor potentially explaining its improved in vivo activity over comparators against tissue cage infections by MSSA strain I20.

After the tissue-cage infection model was established, the animals were treated with multiple dosing, which was consistent with the actual situation of clinical treatment.

The current study characterized the in vivo response of a clinical E.coli strain to cefquinome in a piglet tissue-cage infection model after different dosing.

The aim of this study was to characterize the PK/PD parameter that is predictive of the efficacy of cefquinome against the clinical E.coli strain in a piglet tissue-cage infection model for the first time.

Therefore, in the present study, we collected 210 E.coli clinical strains isolated from pigs with common colibacillosis, and one strain whose minimum inhibitory concentration (MIC) equals to the MIC90 of 210 strains was used for tissue-cage infection model.

One feasible system is the tissue-cage infection model [ 4, 14], which used a tissue-cage with holes on its surface implanted surgically into subcutaneous tissue of an animal.

Tissue-cage infection model was established in piglets, and then the animals received intramuscular injection of cefquinome twice a day for 3 days to create a range of different drug exposures.

Simultaneously, avermectin (1.8 g L−1 a.i. in 1000-fold dilution, 2.5 L ha−1) and triazophos (20% a.i. in 1000-fold dilution, 1500 g ha−1) for C. suppressalis were applied twice in the cages without infection.